{"Symbol": "ALXO", "AssetType": "Common Stock", "Name": "Alx Oncology Holdings\u00a0", "Description": "ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California.", "CIK": "1810182", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080", "OfficialSite": "https://www.alxoncology.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "289946000", "EBITDA": "-107669000", "PERatio": "None", "PEGRatio": "None", "BookValue": "0.836", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-2.01", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.505", "ReturnOnEquityTTM": "-1.19", "RevenueTTM": "0", "GrossProfitTTM": "107000", "DilutedEPSTTM": "-2.01", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-1", "AnalystTargetPrice": "3.333", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "3", "AnalystRatingHold": "1", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "5906.24", "PriceToBookRatio": "6.49", "EVToRevenue": "4254.36", "EVToEBITDA": "-2.349", "Beta": "0.518", "52WeekHigh": "2.62", "52WeekLow": "0.404", "50DayMovingAverage": "1.532", "200DayMovingAverage": "1.107", "SharesOutstanding": "131197000", "SharesFloat": "12749900", "PercentInsiders": "2.898", "PercentInstitutions": "73.160", "DividendDate": "None", "ExDividendDate": "None"}